A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
Type of Study: Clinical Trial
Sponsor / Support: Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU), Frontier Science Foundation, Roche
Primary Objectives: To evaluate the efficacy of adjuvant Atezolizumab + T-AC/EC compared with T-AC/EC alone in patients with TNBC
Design: This is a randomized clinical trial for triple-negative breast cancer patients who underwent surgical treatment and assesses whether the inclusion of ATEZOLIZUMAB (immunotherapy) is likely to increase the chances of cure.
Sample Size: 2.300 patients
Principal Investigator: Gustavo Werutsky (Steering Committee – LACOG)
Countries LATAM: Brazil and Mexico
LACOG 1518 – Bladder Cancer Registry
LACOG 0515 – Testicular Registry
LACOG 0217 – IRONMAN
LACOG 1818 – Prostate Cancer Registry
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0519 – PEACE III